louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05779098: A Machine Learning Architecture to Predict Post-Hepatectomy Liver Failure Using Liver Regeneration Biomarkers and Time-Phased Data
Official title: A Machine Learning Architecture to Predict Post-Hepatectomy Liver Failure Using Liver Regeneration Biomarkers and Time-Phased Data
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Failure After Operative Procedure
Lead sponsor: Eastern Hepatobiliary Surgery Hospital
Sponsor class: OTHER
Collaborators: name: Shanghai 10th People's Hospital
name: Jinling Hospital, China
First posted: 2023-03-22
Enrollment: 1071
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Extensive Hepatology in our hospital

Brief summary: Post-hepatectomy liver failure (PHLF) is the leading cause of morbidity and mortality following major hepatectomy. Existing prediction models fail to capture the dynamic liver regeneration and perioperative changes, limiting their predictive accuracy. We aimed to develop a machine learning (ML) modelling system (PILOT architecture) integrating liver regeneration biomarkers with time-phased perioperative clinical data to accurately predict PHLF risk.


Eligibility criteria: Inclusion Criteria:

Extensive hepatectomy in our hospital（≥ three Hepatic segment）

Exclusion Criteria:

Serious basic diseases Intolerable surgery Refuse to perform ICG test before operation

Primary outcomes:
measure: Postoperative liver failure
timeFrame: 1-5 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Hepatobiliary and Pancreatic Surgery, Tenth People's Hospital of Tongji University, School of Medicine, Tongji University, Shanghai, China
Study officials:
References:
Clinical trial NCT01725698: The Combined Effect of Mesenchymal Stem Cell, HA-CaSO4,BMP-2, and Implant in Inducing The Healing of Critical-Sized Bone Defect
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Union
Lead sponsor: Indonesia University
Sponsor class: OTHER
First posted: 2012-11-14
Enrollment: 5
Sex: ALL
Minimum age (years): 17
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research is aimed to evaluate the combination of mesenchymal stem cell, HA-CaSO4, BMP-2, and implant in treating critical-sized bone defect.

In the presence of critical-sized bone defect whose defect size is more than 2.5 cm, bone will suffer a healing disturbance. In treating these conditions, the conventional method were vascularised bone grafting and bone transport. But the existing methods of treatment have many weaknesses Vascularized bone graft is a procedure with a high level of difficulty. Hence not every orthopaedic surgeon were able to perform it. It also takes more operating time and its failure rate is also quite high.

Meanwhile, external fixation which is applied with bone transport, was being often complained by the patient in terms of cosmetic and psychologically.

According to diamond concept of bone healing, there are four main factors that influence the bone healing. These factors are osteogenic factor (mesenchymal stem cell), osteconductive factor (HA-CaSO4), osteoinductive factor (bone morphogenetic protein-2) and mechanical component (implant). The potency of each component in fracture healing with/out bone defect has been proved in many studies. The combined effect of these components is often studied as well, but not in critical-sized bone defect.


Eligibility criteria: Inclusion Criteria:

* subjects with critical size defect of bone

Exclusion Criteria:

* subjects with patological fracture caused by primary or secondary bone malignancy, imunological deficit, active hepatitis or those who's under immunosuppresant therapy or other therapeutic modality that can interferes with bone healing.

Primary outcomes:
measure: RADIOGRAPHIC UNION SCALE (RUST Score) as a measure of bone union
timeFrame: Before surgery, after surgery, week 4 , 8, 12, 16, 20, 24 up to 1.5 years
Secondary outcomes:
measure: Visual analog scale as the measure of clinical union
timeFrame: Before surgery, after surgery, week 4 , 8, 12, 16, 20, 24 up to 1.5 years
Other outcomes:
Locations:
city: Jakarta, Singapore
country: Indonesia
facility: University of Indonesia, National University of Singapore
state: Indonesia, Singapore
Study officials:
References:
citation: Dilogo IH, Phedy P, Kholinne E, Djaja YP, Fiolin J, Kusnadi Y, Yulisa ND. Autologous mesenchymal stem cell implantation, hydroxyapatite, bone morphogenetic protein-2, and internal fixation for treating critical-sized defects: a translational study. Int Orthop. 2019 Jun;43(6):1509-1519. doi: 10.1007/s00264-019-04307-z. Epub 2019 Feb 12.
Clinical trial NCT00264498: Phase II Iressa & Carbo/Gem in NSCLC
Official title: A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Non-Small-Cell Lung Cancer
NSCLC
Lung Cancer
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-12-13
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.


Eligibility criteria: Inclusion Criteria:

* Advanced Non Small cell Lung Cell Lung cancer
* Never received chemotherapy
* Up and about 50% of waking hours

Exclusion Criteria:

* Spread of lung cancer to the brain
* Low level of white blood cells
* Radiotherapy within 4 weeks

Patients were entered to this study, initiated in 2004, before the significance of predictive factors such as smoking history, adenocarcinoma histology and mutation status was described.

Primary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Date of randomization to earliest date of objective disease progression
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Research Site
state: Quebec
Study officials:
affiliation: AstraZeneca
name: AstraZeneca Canada Oncology Medical Director, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04027998: Median Nerve Strain and Applied Pressure Measurement in the Carpal Tunnel Syndrome Patients
Official title: Median Nerve Strain and Applied Pressure Measurement in the Carpal Tunnel Syndrome Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Carpal Tunnel Syndrome
Lead sponsor: Tokyo Medical University
Sponsor class: OTHER
First posted: 2019-07-22
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: carpal tunnel syndrome patients and asymptomatic control

Brief summary: The aim of this study is to investigate diagnostic accuracy of median nerve strain and applied pressure measurement . Idiopathic carpal tunnel syndrome patients and healthy controls will be evaluated by ultrasound. Median nerve strain, pressure applied to the skin will be measured at the proximal part of the carpal tunnel. The parameters will be compared between patients and controls, and before and after the open carpal tunnel release in the patients.

Detailed description: The aim of this study is to investigate diagnostic accuracy of median nerve strain and applied pressure measurement . Idiopathic carpal tunnel syndrome patients and healthy controls will be evaluated by ultrasound. Median nerve strain, pressure applied to the skin, and ratio of pressure-strain will be measured at the proximal part of the carpal tunnel. In addition, distal latencies in the motor and sensory nerve conductions studies and cross-sectional area of median nerve will be measured. The parameters will be compared between patients and controls, and before and after the open carpal tunnel release in the patients.

Eligibility criteria: Inclusion Criteria:

* carpal tunnel syndrome patients and asymptomatic control

Exclusion Criteria:

* Patients were excluded if there was a history of cervical radiculopathy, rheumatoid arthritis, gout, hemodialysis, sarcoidosis, amyloidosis, or traumatic injuries to the arm. Written consent was obtained from all study participants

Primary outcomes:
measure: median nerve strain
timeFrame: through study completion, an average of 1 year
measure: applied pressure
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Ami
country: Japan
facility: Tokyo Medical University Ibaraki Medical Center
state: Ibaraki
Study officials:
affiliation: Tokyo Medical University Ibaraki Medical Center
name: Yuichi Yoshii
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yoshii Y, Tung WL, Yuine H, Ishii T. Postoperative diagnostic potentials of median nerve strain and applied pressure measurement after carpal tunnel release. BMC Musculoskelet Disord. 2020 Jan 11;21(1):22. doi: 10.1186/s12891-019-3033-y.
Clinical trial NCT03819998: Serum Fetuin Level in Polycystic Ovary Syndrome
Official title: Serum Fetuin Level as a Marker in Polycystic Ovary Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Polycystic Ovary
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
Collaborators: name: Cairo University
name: National Research Centre, Egypt
First posted: 2019-01-29
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: women who have PCOS and have symptoms of hyperandrogenism and irregular cycles

Brief summary: polycystic ovary syndrome is a common gynecological problem

Detailed description: Understanding the pathophysiology and the cause is of much importance for proper management of this problem

Eligibility criteria: Inclusion Criteria:

* women who have PCOS in group 1 and who donnot have PCOS in group 2 with age between 20 -42 years

Exclusion Criteria:

* women above 42 years old

Primary outcomes:
measure: The number of women who will have high level of fetuin A and has PCOS
timeFrame: within a week
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Algazeerah and Kasralainy hospital
Study officials:
References:
Clinical trial NCT01252498: Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis
Official title: A Pilot Study to Evaluate the Role of Cyclooxygenase Pathway in Radiation Therapy and Chemoradiation Therapy Induced Mucositis in Head and Neck Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer of the Head and Neck
Radiotherapy
Keywords: Cancer of the head and neck
Radiotherapy
Prostaglandins
Lead sponsor: University of Vermont
Sponsor class: OTHER
First posted: 2010-12-03
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receiving radiotherapy or chemoradiotherapy for oral cancers. Consecutive patients will be invited to participate.

Brief summary: This study will evaluate the role of cyclooxygenase pathways in radiation-induced and chemoradiation-induced mucositis.

Detailed description: Oral mucositis is a significant toxicity of radiation therapy and chemoradiation therapy in head and neck cancer patients. However the mechanisms that induce such mucositis are not completely understood. Previous work evaluating mucositis in bone marrow transplant patients has suggested that prostaglandin levels may be associated with the appearance of mucositis.

The present study will measure the levels in saliva of the prostaglandins PGE2 and PGI2 before, during, immediately after, and several weeks after radiotherapy for head and neck cancer. These salivary levels will be correlated with clinical observation of mucositis and patient reporting of pain levels.

Improved understanding of the mechanism of mucositis may lead to the development of more effective targeted agents to prevent this problem.

Eligibility criteria: Inclusion Criteria:

* Histologically proven locoregional Stage 4 squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx
* Receiving radiation therapy or chemoradiation therapy to the oropharynx
* Older than 18 years old
* ECOG performance status of 0-2
* Life expectancy greater than 2 months
* Signed informed consent

Exclusion Criteria:

* Previous chemotherapy for this malignancy
* Previous radiotherapy to the head and neck
* Other cancer diagnosis within the last 5 years except for non-melanoma skin cancer or non-metastatic prostate cancer
* Patient taking NSAIDs

Primary outcomes:
measure: Salivary levels of PGE2 and PGI2 during and after radiotherapy
timeFrame: 10 weeks after initiation of therapy
Secondary outcomes:
measure: Observed mucositis during and after radiotherapy
timeFrame: 10 weeks after initiation of radiotherapy
measure: Patient reports of oral pain during and after radiation therapy
timeFrame: 10 weeks after initiation of radiotherapy
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Fletcher Allen Health Care
state: Vermont
Study officials:
affiliation: University of Vermont/Fletcher Allen Health Care
name: Claire Verschraegen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00446498: CPAP Versus NPPV in ACPE
Official title: Continuous Positive Airway Pressure Versus Non-Invasive Positive Pressure Support Ventilation in Acute Cardiogenic Pulmonary Oedema: a Prospective Randomised Multicentre Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pulmonary Edema
Lead sponsor: Ospedale S. Giovanni Bosco
Sponsor class: OTHER
First posted: 2007-03-13
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the intubation rate in patients affected by severe cardiogenic pulmonary edema treated with CPAP or NPPV.

Detailed description: Background Although non-invasive ventilation has shown to be an effective treatment for acute cardiogenic pulmonary oedema (ACPO), literature still lacks of multi-centre randomised prospective studies that compares CPAP with NPPV.

Aim of the study was to assess efficacy and safety of CPAP and NPPV in patients with ACPO.

Methods 80 patients with ACPO were randomly assigned to receive CPAP or NPPV (40 for each group) through a face mask.

Inclusion criteria were: severe dyspnoea, respiratory rate \> 30, PaO2/FiO2 \< 200, muscle fatigue.

Main end-points were endotracheal intubation, length of ventilation, hospital length of stay and mortality.

Eligibility criteria: Inclusion Criteria:

* rapid onset of the symptoms
* severe dyspnoea at rest
* respiratory rate \> 30 breath per minute
* use of accessory respiratory muscles
* PaO2/FiO2 \< 200, radiological findings of ACPE

Exclusion Criteria:

* ST elevation myocardial infarction
* hemodynamic instability (systolic arterial pressure \< 90 mmHg
* need for immediate endotracheal intubation (respiratory arrest, bradypnea
* inability to protect the airways, impaired sensorium (agitation or unconsciousness
* inability to clear secretions, respiratory tract infections
* chronic obstructive pulmonary disease (COPD) exacerbation, chronic respiratory failure necessitating long-term oxygen therapy
* pulmonary embolism, pneumonia, recent oesophageal-gastric surgery
* gastrointestinal bleeding
* facial deformities
* haematological malignancy or cancer with Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.

Primary outcomes:
measure: Intubation rate
Secondary outcomes:
measure: time of recovery
measure: hospital length of stay
measure: mortality and improvement in gas exchange
Other outcomes:
Locations:
city: Torino
country: Italy
facility: Ospedale San Giovanni Bosco Medicina d'Urgenza
Study officials:
affiliation: Ospedale San Giovanni Bosco ASL4
name: Giovanni Ferrari, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ospedale San Giovanni Bosco ASL4 Torino Italy
name: Giovanni Ferrari, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01123798: The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers
Official title: The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Compartment Syndrome
Keywords: near infrared spectroscopy
lower extremity injury
Lead sponsor: J&M Shuler
Sponsor class: INDUSTRY
Collaborators: name: United States Department of Defense
name: Somanetics Corporation
First posted: 2010-05-14
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Active duty OIF/OEF military personnel who have been air evacuated from theater to Landstuhl Regional Medical Center (LRMC). Ambulatory, self-care volunteers from the LRMC outpatient spine center will be identified to serve as controls for Cohort 1.

Brief summary: The purpose of this study is to define the reliability and accuracy of Near Infrared Spectroscopy (NIRS) in the detection of intra-compartmental tissue perfusion in injured and noninjured extremities over time. The investigators hypothesize that this technology, combined with vital signs, intracompartmental pressures and clinical examinations, will be useful in diagnosing acute compartment syndrome (ACS), monitoring patients at risk for ACS, and evaluating the adequacy of fasciotomy in patients treated for ACS.


Eligibility criteria: Inclusion Criteria:

* 18-65 years old
* male or female
* active duty servicemen who have been evacuated from OIF or OEF through LRMC

Exclusion Criteria:

* patients not willing to provide consent
* patients in whom application of NIRS monitoring is viewed as an impediment to casualty care

Primary outcomes:
measure: NIRS values in various physiologic states (stable control, critically injured control, lower extremity injury)
timeFrame: 24-48 hours from hospital admission
Secondary outcomes:
Other outcomes:
Locations:
city: Landstuhl
country: Germany
facility: Landstuhl Regional Medical Center
Study officials:
affiliation: Landstuhl Regional Medical Center
name: Brett Freedman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06271798: Effect Of Resistive Exercises Versus Aerobic Exercises On Varicose Veins In Postmenopausal Women
Official title: Effect Of Resistive Exercises Versus Aerobic Exercises On Varicose Veins In Postmenopausal Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Varicose Veins
Keywords: Resistive Exercises
Aerobic Exercises
Varicose Veins
Postmenopausal Women
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-02-22
Enrollment: 44
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study will be to determine the effect of resistive exercises on varicose veins in postmenopausal women, the effect of aerobic exercise on varicose veins in postmenopausal women and to compare between the effect of resistive exercise versus aerobic exercise on varicose veins in post menopausal women.

Detailed description: Varicose veins in the lower extremities present a spectrum of symptoms from cosmetic issues to severe discomfort including telangiectases, reticular veins, edema, pigmentation, and venous ulceration. These veins lead to painful swelling, skin discoloration, and potential complications like thrombosis, and nerve injury, impacting an individual's efficiency and life quality. Exercise, particularly aerobic and resistance training, has shown promise in improving pain severity, functional ability, and venous blood flow.

So, the current study will be conducted to compare between the effect of resistive exercises versus aerobic exercises on varicose veins in postmenopausal women.

Eligibility criteria: Inclusion criteria:

* All women suffering from varicose veins.
* Their age will range from 50 to 65 years.
* Their body mass index will range from 25 to 29.9 kg/m2.
* Voluntary acceptance of participation in the study.

Exclusion Criteria:

* Had history of serious vascular disease as deep venous thrombosis.
* Sensory deficient
* Any dermatological condition that interferes with the procedure.
* Any musculoskeletal or neurological disorders.
* Acute or healed ulcer wounds.
* Any heart disease or pulmonary disease.

Primary outcomes:
measure: Peak popliteal vein velocity
timeFrame: 6 weeks
Secondary outcomes:
measure: Visual analogue scale
timeFrame: 6 weeks
measure: Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-20)
timeFrame: 6 weeks
measure: 6-minute. walk test
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo University
Study officials:
affiliation: Department of Woman's Health, Faculty of physical therapy, Cairo University, Giza, Egypt.
name: Soheir Mahmoud Elkosery, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06482398: Cream Containing Sericin and Turmeric in Psoriasis Patients
Official title: Efficacy and Safety of Cream Containing Sericin and Turmeric in Psoriasis Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Psoriasis
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2024-07-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Psoriasis lesion is divided into two parts. Half of the lesion will apply cream containing sericin and turmeric and another will apply steroid cream (control). The samples will be apply two times a day for 8 weeks. Psoriasis area and severity index, physician global assessment, body surface area of lesion, dermatology life quality index, Itching score, adverse reaction are evaluated before, after using the samples for 4 and 8 weeks.


Eligibility criteria: Inclusion Criteria:

* Age over 18 years
* Patients with body surface area of psoriasis lesion less than 10, have psoriasis area and severity index less than 10 , and no lesion at face, hands,feet, and genital area
* No topical application on psoriasis lesion at least 2 weeks
* Willing to attend the study

Exclusion Criteria:

* Uncontrolled diseases
* Allergic to sericin turmeric and steroid
* Other skin diseases
* Pregnancy and lactation

Primary outcomes:
measure: Psoriasis Area and Severity Index
timeFrame: 8 weeks
Secondary outcomes:
measure: Physician Global Assessment
timeFrame: 8 weeks
measure: Body surface area of lesion
timeFrame: 8 weeks
measure: Dermatology Life Quality Index
timeFrame: 8 weeks
measure: Itching score
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
References: